Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Science

26 Sep 2024

Can You Reverse Aging? Interview with Maxwell Biosciences’ CEO Joshua “Scotch” McClure

Can aging be stopped or even reversed? Micodose sat down with Maxwell Biosciences' CEO to discuss better health and lifespans....

By Jason Najum

Breaking News

5 Jun 2024

FDA Advisory Committee Rejects Lykos’ MDMA Therapy For PTSD

An FDA advisory panel has rejected the approval of MDMA as a treatment for post-traumatic stress disorder (PTSD). The FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) met to review Lykos Therapeutics’...

By Jason Najum

Industry

28 Dec 2023

The Top Psychedelic Stories of 2023

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic...

By Jason Najum

Culture

22 Dec 2023

Santa’s Trippy Origins: Exploring the Psychedelic Roots of Christmas

We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

8 Dec 2023

Terran Biosciences Granted Four Patents for New Forms of Psychedelics

Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of ibogaine derivative tabernanthalog....

By Jason Najum

Breaking News

31 Oct 2023

Cybin Announces Positive Phase 2 Data for Phase 2 Depression Trial

This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint....

By Jason Najum

Law & Politics

20 Oct 2023

Eureka! California City Approves Psychedelic Decriminalization

Eureka, California has become the latest city to decriminalize psychedelic medicines....

By Jason Najum

Culture

19 Oct 2023

Harvard Launches New Study of Psychedelics in Society and Culture

Backed by a $16 million donation, Harvard is creating a new Study of Psychedelics in Society and Culture....

By Jason Najum

Finance

18 Oct 2023

Spravato Sales Lead J&J Third Quarter Results

Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.